Biocartis and Fast-track diagnostics, have entered into a strategic collaboration to develop a range of multiplex infectious disease tests to run on the Biocartis Idylla system. As part of the collaboration, tests from Fast-track diagnostics’ comprehensive infectious disease menu will be developed for use on Biocartis’ innovative molecular diagnostics (MDx) platform, Idylla. Idylla is a fully-automated MDx system that delivers accurate, rapid tests in virtually any setting, from virtually any biological sample type, and without the need for pre-processing or specialist training.
Biocartis and Fast-track diagnostics collaborate on a new approach to infectious disease diagnostics, “syndromic multiplex testing,” which enables the identification of a broader range of disease pathogens in a single test. Most current methods focus on the detection of one or a few pathogens expected to be present in a patient sample. If the sample is negative, a new test will be performed for other pathogens, increasing the time to result. With syndromic multiplex tests, the initial test will not just look for the most likely pathogen, but also for a range of less likely pathogens, preventing the need to retest.
Biocartis aims to provide direct access to personalized medicine for patients worldwide by developing fully integrated and broadly applicable molecular diagnostics. Fast-track diagnostics specializes in the design, development and manufacture of infectious disease detection kits that use real time PCR.
Subscribe to PharmaTutor News Alerts by Email >>
